- Home
- TRMD vs ARWR Comparison
TRMD vs ARWR Comparison
Compare TRMD & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- ARWR
- Stock Information
- Founded
- TRMD 1889
- ARWR 2003
- Country
- TRMD United Kingdom
- ARWR United States
- Employees
- TRMD N/A
- ARWR N/A
- Industry
- TRMD Marine Transportation
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- ARWR Health Care
- Exchange
- TRMD Nasdaq
- ARWR Nasdaq
- Market Cap
- TRMD 1.9B
- ARWR 1.8B
- IPO Year
- TRMD N/A
- ARWR 1993
- Fundamental
- Price
- TRMD $16.21
- ARWR $13.25
- Analyst Decision
- TRMD Buy
- ARWR Buy
- Analyst Count
- TRMD 1
- ARWR 11
- Target Price
- TRMD $23.00
- ARWR $41.44
- AVG Volume (30 Days)
- TRMD 593.4K
- ARWR 1.7M
- Earning Date
- TRMD 05-08-2025
- ARWR 05-12-2025
- Dividend Yield
- TRMD 31.43%
- ARWR N/A
- EPS Growth
- TRMD N/A
- ARWR N/A
- EPS
- TRMD 4.73
- ARWR N/A
- Revenue
- TRMD $1,444,200,000.00
- ARWR $2,500,000.00
- Revenue This Year
- TRMD N/A
- ARWR $4,380.43
- Revenue Next Year
- TRMD N/A
- ARWR $64.24
- P/E Ratio
- TRMD $3.42
- ARWR N/A
- Revenue Growth
- TRMD N/A
- ARWR N/A
- 52 Week Low
- TRMD $13.60
- ARWR $9.57
- 52 Week High
- TRMD $40.47
- ARWR $30.41
- Technical
- Relative Strength Index (RSI)
- TRMD 47.61
- ARWR 49.13
- Support Level
- TRMD $16.24
- ARWR $13.00
- Resistance Level
- TRMD $17.40
- ARWR $14.97
- Average True Range (ATR)
- TRMD 0.40
- ARWR 0.77
- MACD
- TRMD 0.14
- ARWR 0.16
- Stochastic Oscillator
- TRMD 41.95
- ARWR 57.21
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.